Volume 16 Number 5 (March 1st, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando) A
Volume 16 Number 5 (March 1st, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Richard Stone
George Canellos
Dasatinib: Durable Responses in Chronic Myeloid Leukemia
Richard Stone, Dana-Farber Cancer Institute, BostonCOMMENT:George Canellos, Dana-Farber Cancer Institute, Boston
Data released at the ASH conference show that dasatinib has given durable responses in patients with chronic phase chronic myeloid leukemia for whom imatinib has failed, or who cannot tolerate imatinib. In AtlantaRichard Stonediscussed his findings with Derek Thorne, who then askedGeorge Canellosto reflect on them.
Anton Hagenbeek
George Canellos
Ibritumomab Benefits Patients With Follicular Lymphoma
Anton Hagenbeek, University of UtrechtCOMMENT:George Canellos, Dana-Farber Cancer Institute, Boston
In patients with advanced-stage follicular non-Hodgkin’s lymphoma the radiolabeled antibody ibritumomab tiuxetan prolonged progression-free survival, according to a study reported at the ASH meeting. Sarah Maxwell spoke to the authorAnton Hagenbeek.George Canellosput the data into context.
Charles Hsu
Robert Mayer
Adjuvant Chemoradiotherapy: Sizable Gains In the Treatment of Pancreas Cancer
Charles Hsu, Johns Hopkins University, BaltimoreCOMMENT:Robert Mayer, Dana-Farber Cancer Institute
Patients with resectable pancreas cancer lived longer when treated with adjuvant radiation plus chemotherapy, according to a study reported at the gastrointestinal cancers conference in Orlando.Charles Hsutalked with Peter Goodwin about their findings;Robert Mayerassessed the work.
Pierre Fenaux
Azacitidine New Standard In High Risk Myelodysplastic Syndromes
Pierre Fenaux, Hôpital Avicenne, Paris
Phase III study results presented at ASH found the hypomethylating agent azacitidine was best for patients with high-risk MDS.Pierre Fenauxgave the details to Derek Thorne, who also heard fromGeorge Canellos.
Bart Barlogie
Total Therapy Possible Cure For Multiple Myeloma?
Bart Barlogie, University of Arkansas, Little Rock
The total therapy clinical studies of multiple myeloma reported promising findings to the Hematologic Malignancies Congress in Paris.Bart Barlogietalked with Peter Goodwin about the new data from melphalan-induced tandem autologous transplants with additional thalidomide or bortezomib therapy.
To subscribe to the ASCO Audio Journal of Oncology podcast please go toASCO Audio Journal of Oncology in Advance Presentationsorclick here.
Related Episodes
Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia
Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.
Juan Du MD PhD, ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma
Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.
María-Victoria Mateos; ASH 2025: Unprecedented Survival Benefits with BCMA/CD3 Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma: Majestec-3 Study Findings
This podcast episode, recorded at ASH 2025, features an interview with María-Victoria Mateos MD PhD, who discusses groundbreaking findings from the Majestec-3 study. The study highlights unprecedented survival benefits with the BCMA/CD3 bispecific antibody teclistamab. In patients with relapsed or refractory multiple myeloma, adding teclistamab to standard second-line therapies significantly improved progression-free and overall survival.